Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.bms.com
Press Release
Get the latest updates from Press Release directly as they happen.
Follow now 142 followers
Latest posts
Last updated over 3 years ago
Bristol Myers Squibb to Participate in Citi’s 15th Annual BioPharma Virtual Conference
over 3 years ago
Dateline City NEW YORK NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today...
U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
over 3 years ago
Dateline City PRINCETON, N.J. In the QUAZAR® AML-001 study, Onureg significantly improved...
Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
over 3 years ago
Dateline City PRINCETON, N.J. DAYBREAK trial represents longest safety and efficacy analysis...
Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia
over 3 years ago
Dateline City PRINCETON, N.J. PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced...
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
over 3 years ago
Dateline City NEW YORK & MONTREAL Forbius’s Lead TGF-beta Asset, AVID200, is...
Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program
over 3 years ago
Dateline City NEW YORK & WALTHAM, Mass. Agreement Includes DF6002, With Potential...
Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts
over 3 years ago
Dateline City PRINCETON, N.J. Five–year commitment builds on long-standing investment in health...
CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers
over 3 years ago
Dateline City PRINCETON, N.J. Opdivo is the first and only PD-1 inhibitor...
CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
over 3 years ago
Dateline City PRINCETON, N.J. Opdivo is the first and only treatment to...
Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
over 3 years ago
Dateline City PRINCETON, N.J. CheckMate -743 is the first and only Phase...
Bristol Myers Squibb Reports Second Quarter 2020 Financial Results
over 3 years ago
Dateline City NEW YORK Reports Second Quarter Revenues of $10.1 Billion Posts...
The Bristol-Myers Squibb-Pfizer Alliance is pleased with the U.S. District Court decision to uphold both the composition of matter (COM) patent (US 6,967,208) and formulation patent (US 9,326,945) covering Eliquis®.
over 3 years ago
Dateline City PRINCETON, N.J., and NEW YORK, N.Y. Contacts Bristol-Myers Squibb Media:...